Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1994.12.1.60PMID 8270985
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

  2005cited by this paper
• Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum

  2004cited by this paper
• Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.

  1992cited by this paper
• Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

  1992cited by this paper
• Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.

  1992cited by this paper
• PROLONGED ADMINISTRATION OF ORAL ETOPOSIDE IN PREVIOUSLY TREATED EPITHELIAL OVARIAN CANCER. A PHASE II TRIAL

  1992cited by this paper
• A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

  1991cited by this paper
• Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.

  1991cited by this paper
• Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

  1990cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or Carboplatin

  1990cited by this paper
• A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

  1989cited by this paper
• Chronic daily administration of oral etoposide--a phase I trial.

  1989cited by this paper
• Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

  1989cited by this paper
• How large should a phase II trial of a new drug be?

  1987cited by this paper
• Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.

  1986cited by this paper
• Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.

  1985cited by this paper

• The Potential Role of Phytochemicals of Juniperus procera in the Treatment of Ovarian Cancer and the Inhibition of Human Topoisomerase II Alpha Activity

  2024cites this paper
• Cell cycle and Age-Related Modulations of Mouse Chromosome Stiffness

  2024cites this paper
• Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs

  2023cites this paper
• Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer

  2022cites this paper
• Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer

  2022cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

  2021cites this paper
• Epithelial ovarian cancer: Genomic landscape and evolving precision treatment

  2021cites this paper
• Oral etoposide for treatment and/or maintenance treatment of recurrent epithelial ovarian cancer

  2020cites this paper
• Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The Izmir oncology group (IZOG) study

  2020cites this paper
• Gynecologic Cancers: Ovarian Cancer

  2019cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2018cites this paper
• Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis*

  2018cites this paper
• Treatment of Recurrent Epithelial Ovarian Cancer

  2017cites this paper
• Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer

  2017cites this paper
• Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

  2017cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy

  2017cites this paper
• Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide

  2016cites this paper
• Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives

  2016cites this paper
• F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

  2016cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2015cites this paper
• Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.

  2014cites this paper
• Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004–02

  2013cites this paper
• Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

  2013cites this paper
• Oral Etoposide for the Treatment of Recurrent Ovarian Cancer

  2012cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• Feasibility of Intravenous Gemcitabine and an Intraperitoneal Platinum Agent in the Treatment of Ovarian Cancer

  2011cites this paper
• Bevacizumab and its use in epithelial ovarian cancer.

  2011cites this paper
• ХИРУРГИЧЕСКОЕ И ХИМИОТЕРАПЕВТИЧЕСКОЕ ЛЕЧЕНИЕ РАСПРОСТРАНЕННОГО РАКА ЯИЧНИКОВ

  2011cites this paper
• Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy

  2011cites this paper
• Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

  2011cites this paper
• A Pilot Study of Gemcitabine and Epirubicin Combination Chemotherapy as a Salvage Regimen for Recurrent Platinum Resistant and/or Refractory Epithelial Ovarian Cancer

  2011cites this paper
• Recent progress in the diagnosis and treatment of ovarian cancer

  2011cites this paper
• Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

  2011influential citation
• Comparison of the efficacy between topotecan‐ and belotecan‐, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience

  2010cites this paper
• Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

  2009cites this paper
• A Case of Relapse Ovarian Cancer Treated with Weekly Cisplatn and Daily Oral Etoposide

  2009cites this paper
• Oral etoposide for refractory or recurrent epithelial ovarian cancer.

  2009cites this paper
• Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer

  2009cites this paper
• Phase I/IIa Study of Combination Chemotherapy with CKD‐602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer

  2009cites this paper
• Management of recurrent ovarian carcinoma: current status and future directions.

  2009cites this paper
• Significance of anemia in cancer chemotherapy

  2008cites this paper
• Ovaries and Fallopian Tubes

  2008cites this paper
• Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.

  2007cites this paper
• New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.

  2007cites this paper
• Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.

  2007cites this paper
• LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OFTHE OVARY

  2006cites this paper
• Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

  2006influential citation
• Topoisomerase II inhibitors.

  2006cites this paper
• Salvage Therapy with Oral Etoposide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2006cites this paper
• Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.

  2006cites this paper
• The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.

  2006cites this paper
• Topoisomerase II inhibitors.

  2005cites this paper
• Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.

  2005cites this paper
• Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

  2005influential citation
• Multimodales Management maligner Ovarialtumore

  2005cites this paper
• LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY

  2005cites this paper
• Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.

  2005cites this paper
• Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

  2005cites this paper
• Review of gemcitabine‐based combinations for platinum‐resistant ovarian cancer

  2005cites this paper
• New oral drugs in older patients: a review of idarubicin in elderly patients.

  2004cites this paper
• Review of gemcitabine-based combinations for platinum-resistant ovarian cancer

  2004cites this paper
• A Caelyx helye a petefészekrák másodvonalbeli kezelésében

  2004cites this paper
• Phase II Study of Ifosfamide Plus Daily Oral Etoposide in Previously Treated Ovarian Cancer: A Hoosier Oncology Group (HOG) Study

  2004cites this paper
• Chapter 32 – Decision-Making in the Management of Recurrent Epithelial Ovarian Cancer

  2004cites this paper
• Chapter 34 – Chemotherapy for Refractory Epithelial Ovarian Cancer

  2004cites this paper
• Prolonged daily administration of oral etoposide in lymphoma following prior therapy with Adriamicin, an ifosfamide-containing salvage combination, and intravenous etoposide

  2004cites this paper
• Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel

  2004cites this paper
• Pharmacokinetic Optimisation of Treatment with Oral Etoposide

  2004cites this paper
• Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma

  2003cites this paper
• Chemotherapie des Ovarialkarzinoms

  2003cites this paper
• Second-line chemotherapy of epithelial ovarian cancer

  2003cites this paper
• Platinum-Resistant and Refractory Ovarian Cancer

  2003cites this paper
• Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.

  2003cites this paper
• Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

  2003cites this paper
• Topoisomerase II inhibitors.

  2003cites this paper
• Chemotherapeutic management of advanced ovarian cancer.

  2003cites this paper
• Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer

  2003cites this paper
• Chimiothérapie du carcinome ovarien

  2003cites this paper
• Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients

  2003cites this paper
• Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy

  2002cites this paper
• The role of topoisomerase inhibitors in gynaecological oncology

  2002cites this paper
• Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

  2002cites this paper
• Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer

  2002cites this paper
• Phase I Escalation of Gemcitabine Combined with Protracted Oral Etoposide in Gynecologic Malignancies – A Gynecologic Oncology Group Study

  2002cites this paper
• Chemotherapy for advanced epithelial ovarian carcinoma.

  2002cites this paper
• Weekly platinum chemotherapy for recurrent ovarian cancer

  2002cites this paper
• A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

  2002cites this paper
• Role of chemotherapy in the management of ovarian cancer

  2002cites this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cites this paper
• Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells.

  2001cites this paper
• Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.

  2001cites this paper
• A Systematic Overview of Chemotherapy Effects in Ovarian Cancer

  2001cites this paper
• Oral etoposide following combination chemotherapy and radiation therapy in a patient with advanced adult neuroblastoma led to long survival

  2001cites this paper
• Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group

  2001cites this paper
• Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

  2001cites this paper
• The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.

  2001cites this paper
• The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.

  2001cites this paper
• Treatment of advanced ovarian cancer.

  2001cites this paper
• A systematic overview of chemotherapy effects in ovarian cancer.

  2001cites this paper